Author： Spinelli Antonella
Publisher： Adis International
ISSN： 1173-2563
Source： Clinical Drug Investigation, Vol.27, Iss.1, 2007-01, pp. : 15-33
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Alosetron and irritable bowel syndrome
By Mayer Emeran A Bradesi Sylvie
Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 11, 2003-11 ,pp. :
Access to resources
Recommend
Quality of Life in Irritable Bowel Syndrome
PharmacoEconomics, Vol. 19, Iss. 6, 2001-06 ,pp. :
Serotonergic modulation and irritable bowel syndrome
By Borman R.
Expert Opinion on Emerging Drugs, Vol. 6, Iss. 1, 2001-04 ,pp. :
Rifaximin for the treatment of irritable bowel syndrome
By Cremonini Filippo Lembo Anthony
Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 3, 2012-02 ,pp. :
Emerging treatments for irritable bowel syndrome
By Ahn Joseph Ehrenpreis Eli D
Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 1, 2002-01 ,pp. :